TSE:4527Personal Products
How Investors May Respond To Rohto Pharmaceutical (TSE:4527) Upgraded FY2027 Guidance Despite Softer EPS
Rohto Pharmaceutical Co., Ltd. reported past first-quarter 2026 results with sales rising to ¥91,624 million while net income eased to ¥10,650 million, leading to lower basic and diluted earnings per share from continuing operations year on year.
At the same time, the company raised its full-year fiscal 2027 earnings guidance, citing stronger-than-expected performance in Asia, Japan, and Europe and updated foreign exchange assumptions for the US dollar and Chinese yuan.
Next, we’ll examine...